Inactivity of peptidase ClpP causes primary accumulation of mitochondrial disaggregate ClpX with its interactors at the nucleoid and RNA granule

Jana Key 1, Sylvia Torres-Odio 1,2, Nina C. Bach 1, Suzana Gispert 1, Gabriele Koepf 1, Marina Reichmeier 1,4, A. Phillip West 2, Holger Prokisch 5, Peter Freisinger 6, William G. Newman 7,8, Stavit Shalev 9, Stephan A. Sieber 3, Ilka Wittig 10,11, Georg Auburger 11

Abstract: Biallelic pathogenic variants in CLPP, encoding mitochondrial matrix peptidase ClpP cause a rare autosomal recessive condition, Perrault syndrome type 3 (PRLTS3). It is characterized by primary ovarian insufficiency and early sensorineural hearing loss, often associated with progressive neurological deficits. Mouse models showed that accumulations of (i) its main protein interactor, the substrate-selecting AAA+ ATPase ClpX, (ii) mitoribosomes, and (iii) mtDNA nucleoids are main cellular consequences of ClpP absence. However, the sequence of these events and their validity in human remain unclear. Here, we studied global proteome profiles to define ClpP substrates among mitochondrial ClpX interactors, which accumulated consistently in ClpP-null mouse embryonal fibroblasts and brain. Validation work included novel ClpP-mutant patient fibroblast proteomics. ClpX co-accumulated in mitochondria with POLDIP2 as nucleoid component, LRPPRC as mitochondrial poly(A) mRNA granule element, GFM1 (in mouse also GRSF1) as tRNA processing factors. Only in mouse, accumulated ClpX, GFM1 and GRSF1 appeared in nuclear fractions. Mitoribosomal accumulation was minor. Consistent accumulations in murine and human fibroblasts also affected multimerizing factors not known as ClpX interactors, namely OAT, ASS1, ACADVL, STOM, PRDX3, PC, MUT, ALDH2, PMPCB, UQCRC2 and ACADSB, but the impact on downstream metabolites was marginal. Our data demonstrate the primary impact of ClpXP on the assembly of proteins with nucleic acids, and show nucleoid enlargement in human as a key consequence.
Keywords: Leukodystrophy; Ataxia; Parkinson’s disease; HARS2, LARS2; TWNK; ERAL1; ClpB.

1. Introduction

Primary ovarian insufficiency combined with early onset sensorineural hearing loss, inherited in an autosomal recessive manner, are the clinical hallmarks of Perrault syndrome (PRLTS). As underlying genetic causes, biallelic variants in the genes CLPP, HARS2, LARS2, TWNK, ERAL1, GGPS1, PRORP, or HSD17B4 are identified in 50% of cases, and other putative disease genes are under investigation [1, 2].

For accurate diagnosis and preventive therapy, it is important to understand what subcellular compartments and pathways are disrupted in each genetic subtype of PRLTS, and what crucial events are in common that lead to the selective pathology of Perrault syndrome. The disease-associated genes mostly encode mitochondrial proteins, with HARS2, LARS2 and ERAL1 serving roles for mitoribosomal translation apparatus assembly [3], while PRORP, HARS2 and LARS2 jointly function in tRNA processing of mitochondria [4]. The TWNK gene product Twinkle is well characterized as helicase and primase for mitochondrial DNA, and mitochondrial RNA granules were recently found to need it [5], but no mitoribosomal function has been described to date. Interestingly, one Twinkle isoform is targeted to the nucleus and localizes to the kinetochore during progenitor cell division [6], a fact that might relate to the primary oocyte failure in Perrault syndrome.

A wider spectrum of targets was described for the mitochondrial matrix peptidase ClpP, which plays important roles during the unfolded protein response for mitochondria (UPRmt) [7, 8]. It depends on AAA+ ATPases such as ClpX for activation, substrate selection and disaggregation [9-11]. Two heptameric ClpP rings assemble with hexameric ClpX rings on either side into a barrel-shaped unfolding and degradation machine [12]. In contrast, ClpB as another member of the Clp/Hsp100 AAA+ ATPase family acts to disaggregate proteins in concert with the cognate DnaK/Hsp70 chaperone system, without associating to ClpP or activating degradation [13]. Homozygous deletion of ClpP in mouse was found to trigger accumulated levels of the disaggregase ClpX, mitoribosomes, and mitochondrial nucleoids [14-16], but it remains unclear whether this pathology exists in human and which event is primary. Whether the ClpP-null triggered, on average 1.3-fold accumulation of mitoribosomal proteins depends on the RNA chaperone ERAL1 or other factors, also remains under debate [15, 17]. ClpP deficiency in mouse also causes reduced body size with leanness, even before the manifestation of complete infertility and hearing impairment [14, 18, 19]. Interestingly, ClpP mutant mice and patients affected by Perrault syndrome type 3 (PRLTS3) display not only primary ovarian insufficiency as in other forms of PRLTS, but also azoospermia [14, 20], indicating that germ cell differentiation and meiosis have profound defects, while mitotic proliferation rates of ClpP-null mouse cells appear normal. The PRLTS3 infertility is complete, a phenotype much stronger than the asthenozoosperma usually observed in mitochondrial disorders [21], suggesting that severe extra-mitochondrial pathology may contribute to PRLTS3.

The existence of retrograde signaling about mitochondrial needs and problems to the nucleus has been well established, particularly the communication via calcium release and endoplasmic reticulum signals are well understood [22]. How UPRmt is sensed and executed in the nucleus, can
apparently be mediated by a host of differing mechanisms across phylogenesis [23]. In the age-associated neurodegenerative disorder known as Parkinson’s disease, pathogenic variants of the mitochondrial membrane factor CHCHD2 were shown to stimulate UPR via CHCHD2 nuclear relocalization and via CHCHD10 oligomerization [24-26]. As main nuclear transcriptional response to ClpP-null associated mitochondrial pathology in mice, a massive induction of innate immunity factors was documented, triggered by mtDNA and mitoribosomal stress via the cGAS-STING signaling pathway and by the nuclear accumulation of the co-chaperone DNAJA3 [16, 27-29]. Again, it is unclear if such neuroinflammatory events underlie the PRLTS3 neurodegenerative process in humans.

Here, the identification of initial events of pathogenesis was achieved by a multi-layered approach: Consistency of ClpP-dependent protein accumulations was assessed in global proteome profiles from mouse embryonal fibroblasts (MEF), mouse brain fractions, and skin fibroblasts from patients with biallelic ClpP variants. This was done under the assumption that the comparison of fibroblasts (where energy is mainly generated by glycolysis and downstream mitochondrial Krebs cycle) versus brain tissue (where energy is mainly generated via mitochondrial respiration) would help to define the invariant key ClpXP substrates. We classified accumulated mitochondrial proteins according to evidence, if (i) they are bona fide interactors of the disaggregase ClpX, or (ii) targets of the disaggregase ClpB, or (iii) protein interactors of ClpP itself, or (iv) rather may represent indirect effects due to delayed protein complex turnover and inefficient assembly that are consequence of altered chaperone abundance. To what degree such misassembly of matrix enzymes impacts mitochondrial function, was studied by mouse fibroblast metabolome mass spectrometry and from literature review (scheme in Figure 1). Immunoblots of putative ClpP substrates in subcellular fractions assessed if excess amounts of ClpX and its interactors associate with docking stations outside mitochondria. The findings provide prominent novel insights in how ClpP-inactivity has early preferential ClpX-dependent impact on tRNA processing factors of mitochondria (and possibly nucleus). As variants in other tRNA processing factors such as PRORP, HARS2, LARS2 are a known cause of PRLTS, a common mechanism of disease pathogenesis begins to emerge for Perrault syndrome. In addition, consistent accumulations independent from ClpX were observed for specific vitamin-associated multimerized factors in the mitochondrial matrix.
Figure 1. Schematic overview of experimental setup and main findings. Numbers represent amount of dysregulated factors, red arrows pointing up indicate significant upregulations, blue arrows pointing down indicate downregulations. Number of biological replicates (different cell lines or mice) are represented by non-overlapping symbols, cell line triplicates are shown as overlapping.

2. Materials and Methods

2.1 Mice:

ClpP-null mice had been generated previously [14], were bred from heterozygous matings and were housed under special-pathogen-free conditions with monthly testing of sentinel animals, using a 12 h light cycle with food and water ad libitum in the central animal facility (ZFE) at Frankfurt university hospital. All animal experiments were performed in compliance with the German animal welfare law.

2.2 MEF generation and culture:
Generation and cell culture of mouse embryonic fibroblasts (MEFs) were done as previously described [28]. After intercrosses of ClpP⁺/⁻ mice, WT and ClpP⁻/⁻ MEFs were prepared from embryos at 14.5 days post-coitus. Cells were grown in Dulbecco’s modified Eagle medium (DMEM) (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 1% L-glutamine (Gibco, Thermo Fisher Scientific) and 10% fetal bovine serum (FBS) (Gibco, Thermo Fisher Scientific) in a humidified incubator at 37 °C and 5% CO₂.

2.3 Label-free quantification of proteins in wild type and ClpP-null mouse embryonic fibroblasts:

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE [30] partner repository with the dataset identifier PXD023677. Details to sample preparation, quantitative mass spectrometry and protein identification / quantification are also available in PXD023677. Identifications from reverse decoy database, by site and known contaminants were excluded. Data were further bioinformatically analysed by Perseus 1.5.2.6. [31] and Microsoft Excel. For quantification proteins were quality filtered according to a minimum of 3 valid values in one group (n=3). All missing values from this reduced matrix were replaced by background values from normal distribution. For statistical comparison Student’s t-tests were used. Quantification results are summarized in tables. Data were visualized by volcano plots to highlight the most significant hits. Heatmaps, volcano plots and correlation profiles were generated by Perseus 1.5.2.6.

2.4 Sequential proteome analysis of ClpP⁻/⁻ versus WT mouse brain tissue:

Female 15-month-old WT and age-matched ClpP⁻/⁻ (n=3) mice were sacrificed by decapitation. Their brains were dissected and snap frozen in liquid nitrogen. Frozen brain samples were homogenized in ice cold buffer (150 mM NaCl, 0.5 mM EDTA, 100 mM Tris pH 7.4) using a motor-driven Potter–Elvehjem with 15 strokes. Samples were further sonified with 10 pulses. Following centrifugation at 16,000 rpm for 10 min at 4 °C, the supernatant was transferred to a new tube and precipitated with 20% TCA. The pellet was resolved in extraction buffer (10% SDS, 150 mM NaCl, 50 mM HEPES pH 7.8). Precipitated proteins were washed twice with ice-cold acetone and finally resolved in extraction buffer. Sonification for 5 s facilitated resolubilization of proteins. 100 µg of protein from each fraction was diluted in (4% (w/v) SDS, 100 mM HEPES, pH 7.6, 150 mM NaCl, 0.1 M DTT), mixed with 200 µl 8 M Urea, 50 mM Tris/HCl, pH 8.5 and loaded to spin filters with a 30 kDa cut off (Microcon). The filter aided sample preparation protocol (FASP) [32] was essentially followed. Proteins were digested overnight with trypsin/LysC (sequencing grade, Promega). Following established protocols [33], acidified peptides (final concentration 0.1% v/v trifluoroacetic acid) were fractionated on multi-stop-and-go tips (StageTips) containing C18-tips and strong cation exchange (SCX) tips. Peptides from the pellet fraction were eluted in 3 steps. The C18 translation fraction was combined with the first SXC fraction as well as the second and third SCX fraction. Peptides from the supernatant fraction were eluted in 6 steps. All fractions of each sample were eluted in wells of microtiter plates. Peptides were dried and resolved in 1% acetonitrile, 0.1% formic acid.

Liquid chromatography / mass spectrometry (LC/MS) was performed on Thermo Scientific™ Q Exactive Plus equipped with an ultra-high
performance liquid chromatography unit (Thermo Scientific EASY-nLC) and a Nanospray Flex Ion-Source (Thermo Scientific). Peptides were loaded on a C18 reversed-phase pre-column (Thermo Scientific) followed by separation on a 2.4 µm Reprosil C18 resin (Dr. Maisch GmbH) in-house packed picotip emitter tip (diameter 75 µm, 30 cm long from New Objectives) using a gradient from mobile phase A (4% acetonitrile, 0.1% formic acid) to 30% mobile phase B (80% acetonitrile, 0.1% formic acid) for 75 min following a second gradient to 60% B for another 30 min with a flow rate 250 nl/min. Run was finished by column washout with 99% B for 5 min and reequilibration in 1% B.

Xcalibur Raw files were analysed by proteomics software Max Quant (1.5.3.30) [34]. The enzyme specificity was set to Trypsin, missed cleavages were limited to 2. Acetylation of N-terminus (+42.01) and oxidation of methionine (+15.99) were selected for variable modification, carbamidomethylation (+57.02) on cysteines was set as fixed modification. Mouse proteome set from Uniprot (Download February 2016) was used to identify peptides and proteins. False discovery rate (FDR) was set to 1%. Label-free quantification values were obtained from at least one identified peptide. Identifications from reverse decoy database, by site and known contaminants were excluded. Data were further bioinformatically analysed by Perseus 1.5.2.6. (http://coxdocs.org/doku.php?id=perseus:start) and Microsoft Excel. For quantification proteins were quality filtered according to a minimum of five valid values in one group (n=6). All missing values from this reduced matrix were replaced by background value from normal distribution. For statistical comparison Student’s t-tests were used. Quantification results are summarized in tables. Data were visualized by volcanoplots showing to highlight the most significant hits. Heatmaps, volcano plots and correlation profiles were generated by Perseus 1.5.2.6. Pathway analysis was done by DAVID Bioinformatics Resources 6.7, GOrilla GO [35] and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analysis.

2.5 Metabolome:

For the quantification of 54 metabolic compounds in MEF, 100 mg cell pellets (1x 10^7 cells per line, for 8 WT vs. 8 ClpP^-^-) were snap-frozen in liquid nitrogen, stored at -80 °C and shipped on dry ice to the company Metabolomic Discoveries (Potsdam, Germany). Targeted profiling with unambiguous characterization and relative quantification by LC-tandem mass spectrometry was performed on a Shimadzu triple quadrupole LCMS-8050 equipped with electrospray ionization (ESI) source and operated in multiple reaction mode (MRM). For statistical evaluation, raw data as peak abundances normalized to internal standards and if necessary protein content were detailed, complemented by means and standard deviation values, as well as a Differential Analysis sheet with ANOVA across all groups as global p-value, adjusted global p-value, followed by local p-value from pairwise t-tests and ratios of the group means as log2-value, as well as absolute fold changes. Absolute numbers were normalized against mean of WT samples. Bar graphs were created with GraphPad Prism (GraphPad Software, San Diego, CA, USA) version 9.

2.6 Quantitative immunoblots:
Protein was isolated with RIPA buffer (50 M TRIS/HCl pH 8.0, 150 mM NaCl, 0.1% SDS, 1% triton, 0.5% sodium deoxycholate, 2 mM EDTA, protease inhibitor cocktail (Sigma Aldrich, St. Louis, Missouri, USA) as previously described [14]. Protein content was determined using BCA assay (Life Technologies, Carlsbad, California, USA). 15 µg of protein were loaded for quantitative immunoblotting. Subcellular fractions were done as previously published [28]. Antibodies used were against HSP60 [SantaCruz (Dallas, Texas, USA), sc-13115; 1:500], Lamin A/C [Abcam (Cambridge, UK), ab169532; 1:1000], GAPDH [Calbiochem (Merck Millipore, Darmstadt, Germany), CB1001; 1:1000], CLPX [murine: Invitrogen (Waltham, Massachusetts, USA), PA5-79052; 1:1000; human: Sigma Aldrich, HPA040262; 1:1000], POLDIP2 [Proteintech (Manchester, UK), 15080-1-AP; 1:1000], LRPPRC [Invitrogen, PA5-22034; 1:1000], GRSF1 [Sigma Aldrich, HPA036985; 1:1000], GFM1 [Proteintech, 14274-1-AP; 1:1000], CHCHD2 [Proteintech, 19424-1-AP; 1:1000], OAT [Invitrogen, PA5-92842; 1:1000], MUT [Proteintech, 17034-1-AP; 1:1000].

2.7 Human primary skin fibroblasts:

Skin cells were donated by a 33 year old male Arabic individual with homozygous ClpP mutation (c.[430T>C]; p.[Cys144Arg]; ID-number CB16-0006) who was diagnosed with bilateral sensorineural hearing loss at 14 months of age [20]. The deafness has continuously progressed since. He developed foot drop at 24 years of age with sensory-motor demyelinating axonal peripheral neuropathy of lower limbs upon neurophysiological testing. In adulthood, he was shown to have azoospermia. Further skin cells became available from a 4 year old female Turkish individual with homozygous ClpP mutation (c.[661G>A]; ID-number 58955) leading to open reading frameshift and undetectable ClpP protein in fibroblast immunoblots [36]. This patient in the first week of life already had muscular weakness. At age 2 months, she was diagnosed with microcephaly (1 cm < 3rd percentile) and showed generalized muscular hypotonia. Echocardiography demonstrated mild hypertrophic cardiomyopathy. Metabolic analysis disclosed repeatedly metabolic acidosis with elevated lactate levels (2.8 to 9.0 mmol/l, normal < 2.3 mmol/l). Fumaric acid, 2-oxoglutaric acid, and methylmalonic acid were mildly elevated in urine. Respiratory complex III and IV activity were reduced in muscle biopsy [36]. Subsequently, progressive developmental delay and deafness became evident. She developed epilepsy (West-syndrome). At the time of skin biopsy, she was 5 years of age.

For comparison, primary skin fibroblast cultures from Coriell depository (lines AG06103, AG02261 and AG06858) and other cultures from healthy controls kindly provided by Prof. Henry Houlden (UCLH, UK) (4 cases) were studied. Cell lines were cultivated in DMEM (Gibco, Thermo Fisher Scientific) supplemented with 1% L-glutamine (Gibco) and 10% fetal bovine serum (FBS) (Gibco) in a humidified incubator at 37 °C and 5% CO₂.

2.8 Polymerase Chain Reaction (PCR) to control for Mycoplasma contamination:

200 µl cell culture medium from cultures that had grown for at least 48 h were collected and boiled for 5 min at 95 °C. Samples were centrifuged for 2 min at maximum speed. The PCR reaction mix contained 1 µl sample, 7.4 µl water, 0.8 µl primer forward, 0.8 µl primer reverse, and 10 µl HotStarTaq DNA Polymerase (Qiagen, Hilden, Germany).
Forward primers contained
Myco-5-1: CGCCTGAGTAGTACGTCGC,  
Myco-5-2 CGCCTGAGTAGTACGTCGC,  
Myco-5-3 TGCCTGAGTAGTACATTGC,  
Myco-5-4 TGCCTGAGTAGTACATTGC,  
Myco-5-5 CGCCTGAGTAGTACGTTCGC,  
Myco-5-6 CGCCTGAGTAGTACGTTCGC, 
and reverse primers contained
Myco-3-1 GCGGTGTGTACAAGACCCGA,  
Myco-3-2 GCGGTGTGTACAAAACCCGA,  
Myco-3-3 GCGGTGTGTACAAACCCGA.

Each primer was dissolved to a final concentration of 100 µM, forward and reverse were mixed, respectively, to a final concentration of 10 µM each. PCR was done at the following times and temperatures: 95 ℃ for 5 min, [95 ℃ for 15 sec, 56 ℃ for 15 sec, 72 ℃ for 30 sec] x40, 72 ℃ for 3 min. Samples were run on a 1.5% agarose gel (agarose: Thermo Fisher Scientific).

2.9 Global proteome of human fibroblasts:

Seven control subject cell lines and the two PRLTS3 patient cell lines (in triplicates) were cultured in T75 flasks, washed with PBS (Gibco), and lysed with trypsin (Gibco). The lysates were centrifuged and resuspended in 150 µl lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% NP40, 0.1% sodium deoxycholate, 1 mM EDTA, and protease inhibitor). Protein content was determined using BCA assay (Life Technologies). 300 µg of each sample was precipitated according to the method of Wessel and Flügge [37] and the proteins resuspended in 8 M urea for denaturation. Samples were loaded on molecular cut-off spin columns (Microcon 30 kDa, Merck Millipore) and subsequently reduced, alkylated and digested with trypsin on the filters following the FASP protocol described by Wiśniewski et al. [32]. The obtained peptide mixtures were lyophilized, desalted on 50 mg SepPac C18 columns (Waters) and afterwards fractionated on self-made SCX stage tips (3 disks of SCX material, Empore, in 200 µl pipette tips). Peptides bound to the SCX material were stepwise eluted with five different concentrations of AcONH4 (20 mM, 50 mM, 100 mM, 250 mM and 500 mM), 0.1% TFA, 15% acetonitrile. Overall 65 samples (5 fractions for each of the 13 fibroblast culture samples) were further lyophilized, desalted on self-made C18 stage tips (2 layers of C18 disks, Empore) and after final lyophilization resuspended in 25 µl 0.1% formic acid (FA) and filtered through equilibrated 0.2 µm Millipore filters before mass spectrometry (MS) measurement.

Nanoflow liquid chromatography-MS/MS analysis was performed on an Orbitrap Fusion mass spectrometer (Thermo Fisher) coupled to an UltiMate 3000 Nano HPLC system (Thermo Fisher). Peptides were first loaded on a C18 Acclaim PepMap100 trap column (75 µm ID x 2 cm) and then separated on an Aurora UHPLC analytical column, 75 µm ID x 25 cm, 120 Å pore size (Ionopticks). Columns were constantly heated at 40 ℃. Subsequent separation was performed using a first gradient ranging from 5 to 22% acetonitrile in 0.1% FA for 105 min followed by a second gradient ranging from 22 to 32% acetonitrile in 0.1% FA for 10 min at an overall flow rate of 400 nL/min. Peptides were ionized via electrospray ionization. Measurements on the Orbitrap Fusion were carried out in a top speed data dependent mode using a cycle time of 3 s. Full scan (MS1) acquisition (scan range of 300 – 1500 m/z) was performed in the orbitrap at a defined resolution of 120,000 as well as with an automatic gain control (AGC) ion target value of 2e5 whereby dynamic exclusion was set to 60 s. For fragmentation, precursors with a
charge state of 2-7 and a minimum intensity of 5e3 were selected and isolated in the quadrupole using a window of 1.6 m/z. Subsequent fragment generation was achieved using higher-energy collisional dissociation (HCD, collision energy: 30%). The MS2 AGC was adjusted to 1e4 and 35 ms were selected as the maximum injection time for the ion trap (with inject ions for all available parallelized time enabled). Scanning of fragments was performed by applying the rapid scan rate.

MS Bioinformatics: MS raw files were analyzed with MaxQuant software (version 2.0.3.0). The search was based on the Uniprot human reference protein database downloaded in October 2021, containing 20371 entries. Most default settings of MaxQuant were applied: PSM and protein FDR 1%; enzyme specificity trypsin/P; minimal peptide length: 7; variable modifications: methionine oxidation, N-terminal acetylation; fixed modification: carbamidomethylation. For protein identification the minimal number of unique peptides was set to 2. The match between runs option was enabled. For label-free protein quantification, the MaxLFQ algorithm was used as part of the MaxQuant environment: (LFQ) minimum ratio count: 2; peptides for quantification: unique. Statistical analysis was performed in Perseus (version 1.6.15.0). Proteins identified only by site, reverse hits or potential contaminants were removed. LFQ intensities were log2 transformed. Samples were grouped into two categories: control (7 samples) and PRLTS3 (3 samples for patient 0006, plus 3 samples for patient 58955) and then filtered for at least four valid values in each group. The replicate groups were compared via a two-sided, two-sample Student’s t test (S0 = 0, permutation-based FDR method with FDR = 0.05 and 250 randomizations).

2.10 Immunofluorescence:

Human fibroblasts were grown on 12 mm coverslips 16 h before experiments. The next day, cells were washed with PBS, fixed with 4% paraformaldehyde for 20 min, permeabilized with 0.1% Triton X-100 in PBS for 5 min and blocked with PBS containing 10% FBS for 30 min. After blocking, cells were incubated with primary antibodies for 60 min and stained with secondary antibodies for 60 min. Cells were washed with PBS between each step. Coverslips were mounted with Prolong Gold anti-fade reagent containing DAPI (Molecular Probes, Eugene, OR, USA). Images were collected with Nikon Eclipse Ti2 inverted microscope using a 60X oil-immersion objective and NIS-Elements Advanced Research software, version 5.21.02. Z-stack images were processed using NIS Extended Depth of Focus module to create focused, single plain maximum intensity projection TIFs. Nucleoid area quantification was performed largely as described [16]. Briefly, approximately 3-4 unique fields of view from 3 distinct images (of each genotyping at each treatment) comprising between 800–1000 nucleoids, were captured at random. Scale information was added to Image J, then images were made binary, and the area of each nucleoid was determined using the ‘Analyze Particles’ feature of ImageJ. Nucleoids were divided into 2 sizes cut-offs: <150nm² and >=150nm² and values were plotted as percentage (%). The following antibodies were employed: anti-TFAM [Proteintech, 23996-1-AP; 1:200], anti-HSP60 [Santa Cruz, sc-1052; 1:300], anti-ClpP [Proteintech, 60004-1-LG; 1:200], anti-DNA [Millipore, CBL-186 AC-30-10; 1:300].

2.11 Quantitative polymerase chain reaction (qPCR):


Total cellular DNA was isolated with 250 µl (12-well plate) of 50 mM NaOH and boiled for 30 min to solubilize DNA. 25 ml of 1 M Tris-HCl pH 8 was added to neutralize the pH, and DNA was quantified and diluted to obtain 2 ng/µl concentration. DNA was then subjected to qPCR using Fast SYBR Green Master Mix (Applied Biosystems) and primers indicated below. Three technical replicates were performed for each biological sample, and expression values of each replicate were normalized against KIR4 using the 2-ΔΔCt method. Results were plotted as relative mtDNA abundance (fold) and control samples were centered at 1. Forward and reverse primer sequences:

For ND1 gene, forward GAACTAGTCTCAAGCTCAACATCG, reverse CTAGGAGATTTGAGTGTTG.
For D-loop, forward CATAAAGCTTTAATAGCCCAACACG, reverse CCGTGAGTGGTTAATAGGGTGAT.
For KIR4 gene, forward GCCGAAAAGCCCTCCTCATT, reverse CTCCTCGTTGTTGTTGG.

### 2.12 Reverse-transcriptase quantitative real-time polymerase chain reactions (RT-qPCR):

Total RNA from snap-frozen cell pellets (n=4 WT vs 4 ClpP−/− MEF lines) was isolated with TRI reagent (Sigma, and DNase (Amplification Grade, Invitrogen) was used for purification of RNA, and SuperScript III (Invitrogen) for reverse transcription following manufacturers’ instructions. qPCR was performed with TaqMan Gene Expression Assays (Applied Biosystems) in cDNA from 20 ng total RNA in 20 µl reactions with 2× master mix from Roche in a StepOnePlus Real-Time PCR System (Applied Biosystems, Waltham, MA, USA). The analysis of the data was carried out with the 2−ΔΔCT method [38]. The following Taqman assays (ThermoFisher) were employed for murine transcripts: ClpP: Mm00489940_m1, ClpX: Mm00488586_m1, Poldip2: Mm00458936_m1, Lrpprc: Mm00511512_m1, Gsf1: Mm00618579_m1, Gfm1: Mm00506856_m1, Chchd2: Mm01742631_s1, Mut: Mm00485312_m1, Oat: Mm00497544_m1, Tbp: Mm00446973_m1.

### 2.13 Bioinformatic analyses:

Global proteome Perseus output data were further analysed employing the STRING webservice ([https://string-db.org/](https://string-db.org/), last accessed on 01. July 2021) for protein-protein interaction and pathway analyses. Filtered gene symbols were entered into the Multiple Proteins option for *Mus musculus* and the graphical output was archived, highlighting factors with identical features by coloring, as explained in figure captions. Significant enrichments of GO (Gene Ontology) terms and KEGG pathways were exported into Excel files. For further protein interaction studies, the biomedical interaction repository BioGrid ([https://thebiogrid.org/](https://thebiogrid.org/), last accessed on 06. Sept. 2021) was used. The interactors for human ClpP, ClpX, and ClpB were searched independently and the BioGRID output data were saved as Excel files. Data were manually filtered for non-redundant factors in separate work sheets and proteins were matched with global proteome data. Overlapping proteins between different data sets were identified by creating Venn diagrams using the website [http://bioinformatics.psb.ugent.be/webtools/Venn/](http://bioinformatics.psb.ugent.be/webtools/Venn/), last accessed on 11. September 2021. An overview of Venn output data is included in Figure 1. Fisher exact test which is implemented in Perseus was used to identify non-random associations between terms in categorical columns. Tables include t-test p values and the Benjamini-Hochberg FDR (multiple
hypothesis testing). Statistical evaluation was done using GraphPad Prism version 9. Bar graphs show variances as standard error of the mean (SEM) and p-values from Welch’s t-test (*p < 0.05; **p < 0.01; ***p < 0.001, ****p < 0.0001).

3. Results

3.1. ClpP-null MEF proteome profile and its bioinformatic analysis.

We aimed to identify ClpP-dependent protein degradation deficits, and to define a sequence of events within mitochondria to elucidate the initial events in PRLTS3 pathogenesis. Primary fibroblasts were prioritized since they are easily available from ClpP-mutant patient skin and from mouse embryos. Cultures of 3 ClpP-null versus 3 age-sex-matched WT MEF were extracted with 10% SDS and analysed with label-free mass spectrometry to survey alterations in protein abundance. Among 5,838 detected factors (Table S1 complete with imputation), 436 were significantly decreased, while 235 showed significantly increased levels. Preferential mitochondrial localization is known for 26 downregulated and 63 upregulated factors (Tables 1A and 1B, respectively). Putative ClpP-dependent degradation substrates would be expected among the latter ones. The absence of ClpP and the previously reported accumulation of its substrate-selecting interactor ClpX [14] were confirmed in the mass-spec spectra.

Imputation was performed to maximize the number of proteins under analysis, and the power of subsequent bioinformatics. Evaluation of significant interaction clusters and pathway enrichment among these factors employed the Fisher algorithm. This approach revealed that the accumulations occurred mainly among extra-mitochondrial proteins of the immune system and the extracellular matrix, while accumulated proteins in mitochondria had smaller number and fold-changes (most of them are known for a role in the RNA metabolic process). In comparison, the reduced protein abundance was clustered among nuclear proteins, in particular the spliceosomal complex (Table S1, further datasheets). It was intriguing to note how mitochondrial ClpP inactivity affects nuclear functions, but the mechanisms of this retrograde signalling require further elucidation. We interpreted the greater fold-changes of extra-mitochondrial factors as evidence that signal amplification is facilitated by nuclear promoters and results in the largest effect sizes for very downstream events. This downstream amplification is a known feature of blood coagulation cascades and phosphorylation cascades. Therefore, in our subsequent quest to identify primary events of pathogenesis, we filtered by significance levels rather than fold-changes.
Table 1A: Mitochondrial proteins (UniProt-IDs) with significant downregulation in ClpP-null MEF versus WT (3 vs. 3). Factors with special relevance for this manuscript are highlighted in bold letters.

| Majority protein IDs | Gene names | p-value  | fold change with imputation |
|----------------------|------------|----------|-----------------------------|
| Q8BWT1;Q3UKH3        | Acab2      | 0.00089  | -1.23                       |
| Q8IZN5               | Acad9      | 0.00237  | -1.26                       |
| F6X5P5;Q6PE15        | Abhd10     | 0.00295  | -1.98                       |
| Q64429;Q80VB2;Q3UTK2;Q9CUA1;Q8BRY0 | Cyp1b1 | 0.00468  | -6.59                       |
| P32020               | Scp2       | 0.00482  | -1.31                       |
| Q3UGW4;Q88696;Q8CF81 | Clpp       | 0.00652  | -14.78                      |
| Q3V471;Q8C253;P16110 | Lgals3     | 0.00772  | -1.18                       |
| O08528;E9Q585        | Hk2        | 0.00975  | -1.34                       |
| Q923F9;E9QXPX3;Q9CXZ1;Q9CTT4 | Ndufs4 | 0.01191  | -1.26                       |
| Q9CRB9;S4R238;Q9D9P1;D3Z0L4;Q91VG6 | Chxd3 | 0.01605  | -1.14                       |
| Q91YP2;Q3UJU1;Q3TB65 | Nin        | 0.01861  | -1.30                       |
| Q9CQ54;Q9D846        | Ndufc2     | 0.01937  | -1.28                       |
| P48771               | Cox7a2     | 0.0195   | -2.71                       |
| Q9Z218;C6EQH3        | Suclg2     | 0.02057  | -1.44                       |
| Q9CQ85;D3Z3X4        | Cisd2      | 0.02114  | -1.23                       |
| Q6GQ1U1;Q3UPC4;Q3TJE3;G3UVV4;P17710;Q3UE51;Q3TTB4 | Hk1 | 0.02184  | -1.11                       |
| X2EXD0;Q920L1        | Fads1      | 0.02262  | -1.44                       |
| A0A0R4I0G0;Q8BH04;Q8R3X7;Q3UGF0 | Pck2 | 0.03043  | -1.20                       |
| Q9CS68;Q9WV84        | Nme4       | 0.03198  | -1.55                       |
| Q8BH95;F6T930        | Echs1      | 0.03524  | -1.23                       |
| Q9CY73;Q99N15;A2AFQ2;Q08756 | Hsd17b10 | 0.0374   | -1.21                       |
| A2AP32;A2AP31;Q3UIU2 | Ndufb6     | 0.04203  | -1.42                       |
| Q9WTP7;Q9D8W6        | Ak3        | 0.04225  | -1.13                       |
| Q9D6U8               | Fam162a    | 0.04271  | -1.36                       |
| Q9DDK2;Q3UK61;Q3U9P7;Q3UIQ9;Q9CRF4 | Ooct1 | 0.04754  | -1.20                       |
| Q8K009;D3Z6B9        | Aldh1l2    | 0.04963  | -1.38                       |
Table 1B: Mitochondrial proteins (UniProt-IDs) with significant upregulation in ClpP-null MEF.

In a more stringent analysis, we focused on those 169 proteins that were significantly upregulated (p<0.03) upon analysis without imputation. These...
potential ClpP substrates were assessed on the STRING web platform, revealing a strongly significant protein-protein-interaction enrichment (p<1.0e-16). STRING generated a diagram of protein-protein interactions that highlights a prominent network of mitoribosomal components and molecular chaperones, as described [11, 15]; in comparison, the assembly factors for iron-sulfur-cluster biosynthesis and respiratory chain elements as well as mitochondrial enzymes played a minor role (Figure S1). The detailed analysis of enrichments (Table S2) also documented the previously reported increase of cytosolic innate immunity mediators [14], and a novel elevation of secreted collagen precursors. Overall, the global proteome profiles of ClpP-null MEFs was in excellent agreement with previous knowledge, but further filtering was needed to identify ClpP substrates with primary role in pathogenesis. It remained unclear how to best eliminate the manifold downstream cell-wide effects.

3.2. Selected dysregulations are reproducible in brain tissue, and reflect direct ClpX impact on interactors.

Thus, we tested if these accumulations occur also in different cell fractions of female 15-month-old ClpP-null mouse brain. At this mouse stage the cell stress of old age becomes already apparent, while senescent multimorbidity has not yet begun. Sequential extractions from the brain tissue were done, first obtaining readily solubilized proteins with RIPA buffer, and subsequently solubilizing the resulting pellets in 2% SDS buffer to study also the more insoluble proteins. After label-free mass spectrometric quantification of individual peptides, the resulting two global proteome profiles from brain extract supernatant and pellet (Table S3) were compared with the initial data from complete MEF (Table S1). The significantly upregulated factors were filtered for consistency among all lists, and filtered for mitochondrial localization, producing a list of 37 potential ClpP degradation substrates (Table S3). In the resulting STRING diagram (Figure 2) and pathway enrichment statistics (Table S4), prominent accumulations of mitoribosomal proteins (blue color) and chaperones are observed as before, mitochondrial nucleoid factors became more prominent (green), with most of these diagram nodes connected to ClpX accumulation. Interestingly, several of the consistently upregulated factors localize not only to mitochondria but in parallel also to the nucleus, particularly the nucleolus (Figure 2).
ClpP depends on ClpX for the selection and disaggregation of its substrates, so in our reasoning the accumulation of ClpX and its interactor proteins would be among the initial primary events of pathogenesis in ClpP-mutant cells. To ensure that all available high quality data on endogenous protein complexes enter this analysis, the manually curated BioGrid database entry on human ClpX protein associations was downloaded (Table S5). Among these known ClpX interactors, the ClpP-null fibroblasts and brain tissues exhibited consistent significant accumulations for the AAA+ ATPase ClpX itself, another AAA+ ATPase in mitochondria known as VWA8 (Von Willebrand Factor A Domain Containing 8) [39], the nucleoid component POLDIP2 (also known as PDIP38) (DNA Polymerase Delta Interacting...
Protein 2) [40], the mitochondrial RNA granule component LRPPRC (Leucine Rich Pentatricopeptide Repeat Containing) [41], the mitochondrial precursor RNA processing factor GRSF1 (G-Rich RNA Sequence Binding Factor 1) [42], the mitoribosomal tRNA translocation mediator GFM1 (G Elongation Factor Mitochondrial 1) [43], and the UPRmt sensor CHCHD2 (Coiled-Coil-Helix-Coiled-Coil-Helix Domain Containing 2) [24, 44].

To assess the specificity of these observations, in comparison we assessed the protein interaction list for the AAA+ ATPase ClpB, which is also conserved since bacteria until mammalian mitochondria. Among the ClpB interactor proteins listed in BioGrid, only three components of the small mitoribosomal subunit named MRPS9, MRPS22 and MRPS27 showed consistent significantly upregulated abundance in ClpP-null MEF and brains (Table S5).

In a third BioGrid data mining effort, we looked into ClpP interactor proteins. Significant accumulation in ClpP-null MEF was observed for 37 such factors, among which 19 were also upregulated in ClpP-null brain (Table S5). Interestingly, 6 of them are known to associate with ClpP and with ClpX, but 13 are documented only as ClpP interactors (e.g. OAT, ornithine amino transferase), raising the possibility that ClpP-deficiency might lead to accumulation of degradation substrates that do not interact with ClpX.

Overall, the additional proteomic work to define dysregulation consistency between glycolytic fibroblasts and respiring brain, together with the filtering of dysregulated ClpX protein interactors, permitted us to focus on fewer changes, which are possibly initial events of pathogenesis and are clearly relevant for several cell types. The novel insights could be explained by a scenario where ClpP by itself acts e.g. on the OAT homohexamer that is stably associated with pyridoxal phosphate in the mitochondrial matrix, and ClpB assists the disaggregation of mitoribosomes, while ClpX mediates the targeting of mitochondrial nucleoids together with adjacent RNA granules. ClpX might select substrates for ClpP-mediated cleavage during the assembly and disassembly of mitochondrial DNA / rRNA / mRNA / tRNA with proteins in these complexes. These consistent global proteome effects identified putative substrates, but they failed to clarify whether impaired degradation or reduced biosynthesis are responsible for the effects, and how the mitochondrial pathology triggers the dysregulation of nuclear and nucleolar factors by retrograde signalling.

3.3. Assessment of transcriptional induction.

Therefore, we assessed next if these dysregulations are indeed due to altered protein turnover, as a consequence of absent mitochondrial peptidase ClpP, or are due to secondary transcriptional responses that represent compensatory or deleterious downstream events. Therefore, mRNA levels of these crucial factors were quantified by RT-qPCR and shown to be unchanged, with exception of ClpP mRNA absence (Figure 3). These data indicate that the accumulation of these proteins is not due to nuclear transcriptional upregulation, in agreement with the concept that the protein turnover rate of POLDIP2, LRPPRC, GRSF1, GFM1 and CHCHD2 depends on ClpXP-mediated degradation.

3.4. Validation by immunoblot, with analysis of subcellular distribution.

To validate the protein accumulations by quantitative Western blots, and to test whether the ClpP deficiency triggers accumulation of these
proteins only within mitochondria or also extra-mitochondrially, subcellular fractionations of MEF cells by differential detergent extraction were performed, as previously established [28]. Fractionation purity was controlled by immunoblots with mitochondrial HSP60, cytosolic GAPDH and nuclear Lamin A-C, detecting no mitochondrial contamination in the nuclear fraction, and very little nuclear material in the mitochondrial fraction; even the cytoplasmic contamination was minor in these two fractions (Figure 3A).

Figure 3. Immunoblot validations of mitochondrial accumulation of specific ClpX interactors in ClpP<sup>−/−</sup> (n=3) versus WT (n=3) MEF. Subcellular fractionation quality and loading were controlled by GAPDH, HSP60, or LAMIN A/C protein abundance. Asterisks ** represent p < 0.01; * represents p < 0.05; T represents 0.05 < p < 0.10.
As expected from the mass spectrometry data, the ClpX-immunoreactive band showed accumulation, but unexpectedly this effect was much stronger in the nuclear fraction than in the mitochondrial fraction of MEFs (Figure 3B). This observation represents strong evidence that ClpX selectively targets proteins that are associated with DNA or unspliced RNA, so that excess ClpX amounts would find suitable docking stations mainly in the nucleus.

The analysis of ClpX interactors POLDIP2 (predicted precursor size 42 kDa) and LRPPRC (predicted precursor size 158 kDa) distribution showed their accumulations to be restricted to mitochondria (Figure 3B).

In contrast, antibodies against GRSF1 (predicted precursor full-length size at 55 kDa) and against GFM1 (predicted precursor size at 83 kDa) showed the expected band to accumulate in mitochondria and nucleus. The gain-of-function of the mRNA / tRNA / rRNA / lncRNA processing factor GRSF1 and of the tRNA translocation mediator GFM1, both in mitochondria and nucleus, would probably contribute to mitoribosomal inefficiency. Beyond mitochondrial translation, their excess may also alter nucleolar processing / nuclear export, causing generalized cell stress.

The Parkinson’s disease (PD) associated UPR mt sensor CHCHD2 (predicted precursor size 16-18 kDa) was increased only in the mitochondrial fraction, a slightly smaller band in the nucleus did not show dysregulation. An antibody of sufficient quality for the sensitive and specific detection of VWA8 in MEF was not found.

Overall, the accumulations of ClpX and five ClpX-interactors was confirmed in mitochondria, and ClpX with two interactors showed similarly elevated abundance also in nuclear fractions.

3.5. Conserved ClpX-dependent effects in ClpP-mutant patient skin fibroblasts

Which of these mouse findings can be reproduced in human? Skin primary fibroblast cultures were available to us from two patients with biallelic ClpP variants who had markedly different disease severity (see Materials section), so that the global proteome dysregulations might be expected to be less dramatic in case 0006 than in case 58955.

A completely novel documentation of the global proteome profile of primary skin fibroblasts from these two PRLT53 patients (average values, each in triplicate culture samples) versus seven healthy controls (Table S6, volcano plot in Figure 4A) confirmed undetectable ClpP levels in every mutant cell triplicate upon mass spectrometry (while ClpP was solidly detected in 3 out of 7 controls), and upregulated abundances for the proteins ClpX (average 3.2-fold with p=1.8e-6; in more severe case higher abundance by 1.7-fold), POLDIP2 (average 2.2-fold with p=0.0002; severe case had 1.5-fold more), LRPPRC (average 1.4-fold with p=0.004; severe case 1.5-fold more), GFM1 (average 1.7-fold with p=0.008; severe case 1.7-fold more), GRSF1 (average 5.3-fold with p=0.0002; severe case 1.1-fold more) and MRPS27 (average 1.1-fold with p=0.02; severe case 1.4-fold more). Among these factors, ClpP deficiency affected ClpX and its interactors POLDIP2 and GRSF1 with prominent effect size. CHCHD2, VWA8, MRPS9 and MRPS22 proteins were below detection threshold in this mass spectrometry survey.
Systematic filtering of mitochondrial proteins that were upregulated at least 20% more in the severe case than in the mild case was done to define the molecular correlates of disease severity (Figure 4B). Strong enrichment upon STRING statistics was observed for ClpX and other mitochondrial nucleoid- RNA granule- associated factors (POLDIP2, LRPPRC, FASTKD2, DHX30, MTPAP) [45, 46], but not for mitoribosomal proteins. In addition, the individual with the more severe phenotype showed stronger accumulation of mitochondrial protein processing peptidase components, of 4 iron 4 sulfur cluster binding and heme biosynthesis proteins, as well as of amino acid metabolism enzymes, with significant enrichment upon STRING analysis (Figure 4B; the list of mitochondrial factors with stronger accumulation in case 59855, and their enrichment statistics are found in Suppl. Table S7). Within amino acid metabolism, particularly the valine/leucine/isoleucine, arginine/proline, and glutamate/glutamine pathway components were standing out. Mitoribosomal proteins did not.

Figure 4: (A) Analysis of both PRLTS3 patients’ (in triplicates) versus 7 healthy controls’ skin fibroblast proteome profiles in volcano plots, highlighting the accumulated proteins in mitochondria. The significance threshold at 1.3 on the Y-axis
corresponds to the p-value 0.05, the X-axis shows the traditional cutoff at 1.5-fold effects, although genetic evidence has demonstrated a neurodegenerative process at old age to be triggered by lower gain-of-function, such as 1.3-fold dosage of alpha-synuclein. (B) Analysis of the differences between both patients in a STRING interaction diagram, focused on mitochondrial proteins with significant accumulation in ClpP-mutant patient skin fibroblast global proteome, which showed 1.2-fold stronger change in the severely affected patient 58955 than in the milder patient 0006. (C) Comparing all accumulations with nominal significance in both PRLTS3 fibroblasts that showed consistency with nominal significant accumulations also in ClpP-null MEF, using a Venn diagram, 23 effects were consistent between species, among which all mitochondrial proteins were listed below, employing their gene symbol. (D) Analyses of protein abundance in fibroblasts from a human control (red128) and the patient with stronger fold-changes (58955), controlling the subcellular fractionation purity and loading by GAPDH (cytosolic marker), HSP60 (mitochondrial), or LAMIN A/C (nuclear) abundance. (E) Quantitative immunoblots for CLPX and its protein interactors confirmed their accumulation to be restricted to mitochondria.

3.6. Conserved ClpX-independent effects in ClpP-mutant patient skin fibroblasts

Testing the consistency between the proteome profiles of both PRLTS3 patient fibroblast cultures (in triplicates) versus ClpP-null MEF, we noted also significant accumulations of eleven mitochondrial matrix proteins (Figure 4C), which are not known as interactors of ClpX or ClpB: OAT, ASS1, ACADVL, STOM, PRDX3, PC, MUT, ALDH2, PMPCB, UQCRCC2 and ACADSB, see Table 2. Importantly, all of them are known for their assembly into homo-multimers or heterodimers [47-58]. OAT, PC, ALDH2, PMPCB, ACADSB showed significant accumulation also in ClpP-null brain (Table S3). ClpP-dependent OAT accumulation stands out and was already proposed together with POLDIP2 as putative ClpP substrates in a previous mouse fibroblast proteome study [11] although it was never found to interact with ClpX. PMPCB forms heterodimers with PMPCA and has a key role in mitochondrial precursor protein cleavage / folding as well as presumably UPRmt, in very similar manner as its homologous cleavage factor UQCRCC2 that forms heterodimers with UQCRCC1 and is crucial for respiratory complex III assembly. The above upregulations of several proteins that have to multimerize after mitochondrial import could represent a secondary consequence of the UPRmt stress in fibroblasts that use glycolysis predominantly, where altered abundance of molecular chaperones and altered pH conspire to impair the maturation of functional multimer complexes. However, in the light of our search for ClpP substrates that accumulate in PRLTS3 cells, we might see these factors as primary targets of ClpP dysfunction, which are independent from ClpX. Thus, these proteins might shed light on ClpP basic function.

Table 2: Significant accumulations of the above eleven mitochondrial matrix proteins were consistent between both PRLTS3 fibroblasts and ClpP-null MEF, and partially consistent with ClpP-null brain (highlighted by grey background), although they are not known as interactors of ClpX or ClpB. All of them show multimerized quaternary structure, partly they associate with cofactors.
Beyond mass spectrometry, immunoblot analyses in fibroblast protein subcellular fractions from the severely affected PRLTS3 female 58955 (where fold-changes in abundance can more easily be visualized in quantitative Western blots) and from the control female red 128 were employed to assess data reproducibility in human (Figure 4D-E). Again, accumulations were apparent for ClpX, POLDIP2, LRPPRC, GRSF1, GFM1 bands and CHCHD2 in the mitochondrial fraction. A nuclear accumulation of ClpX and its interactors was not observed, even after using a titer of 1:100 of the anti-ClpX antibody that had detected nuclear ClpX in MEF fractions. While it is therefore doubtful if excess ClpX in the nucleus is a relevant event contributing to PRLTS3 pathogenesis, it may exacerbate pathology in the mouse model.

3.7. Mass spectrometry quantification of amino acids in ClpP-null MEF

| Gene symbol | Function                               | Pathway                             | Cofactor                                    | Quaternary Structure | Reference | PRLTS3 fib. accumulation p-value | PRLTS3 fib. accumulation fold change |
|-------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------|-----------|----------------------------------|-------------------------------------|
| OAT         | ornithine aminotransferase             | amino acid metabolism / urea cycle | pyridoxal-phosphate                         | homo-tetramer        | 49        | 0.00002                          | 3.0                                 |
| ASS1        | arginino-succinate synthase            | urea cycle                          | -                                           | homo-tetramer        | 55        | 0.00006                          | 2.4                                 |
| ACADVL      | very-long-chain acyl-CoA dehydrogenase | fatty acid degradation               | flavin-adenine-dinucleotide (FAD)           | homo-dimer           | 53        | 0.0005                           | 1.5                                 |
| STOM        | ion channel activator                  | innate immune defence                | homo-dimer or homo-oligomer                 |                      | 58        | 0.001                           | 1.8                                 |
| PRDX3       | antioxidant                            | selenium & senescence                | homo-dimer & dodecamer                      |                      | 54        | 0.002                           | 1.3                                 |
| PC          | pyruvate carboxylase                   | amino-fatty acid / glucose metabolism| biotin                                      | homo-tetramer        | 52        | 0.003                           | 1.7                                 |
| MUT         | methyl-malonyl-CoA mutase              | carbon metabolism                    | adenosyl-cobalamin                          | homo-dimer           | 47, 48    | 0.004                           | 1.4                                 |
| ALDH2       | aldehyde dehydrogenase                 | alcohol-oxidation, CoA biosynthesis  | -                                           | homo-tetramer        | 56        | 0.01                            | 2.0                                 |
| PMPCB       | mitochondrial targeting sequence cleavage | proteostasis                        | -                                           | hetero-dimer with PMPCA | 50        | 0.02                            | 1.4                                 |
| UQRC2       | cleavage of complex III components     | respiratory chain assembly           | -                                           | hetero-dimer with UQRC1 | 51        | 0.03                            | 1.4                                 |
| ACADSB      | short / branched chain specific acyl-CoA dehydrogenase | amino acid metabolism | flavin-adenine-dinucleotide (FAD) | homo-tetramer        | 57        | 0.04                            | 1.2                                 |
To understand the downstream consequences of the protein accumulations documented above, on the one hand we assessed the impact of ClpX-independent accumulation of OAT, ASS1, PC, MUT and ACADSB on amino acid metabolism, and on the other hand we assessed the consequences of ClpX-interactor excess on the nucleoids. A metabolomics approach by mass spectrometry was taken to quantify the amino acid concentrations in 8 ClpP-null versus 8 WT MEF (Table S8, Figure S2), since patient fibroblast lines were not available in sufficient numbers to evaluate mild changes. Although variability was high and future tissue analyses may be needed, the preliminary data showed nominal significance (p<0.05) for increased levels of leucine/isoleucine, contrasting with decreased levels of methionine and histidine. The levels of valine, arginine/proline, glutamate/glutamine and in particular ornithine were normal, suggesting that excess multimers as e.g. OAT may be misassembled but normal enzymatic activity remains. Also a previous study of *Podospora anserina* ClpP deletion mutants observed increased leucine/isoleucine, as opposed to decreased histidine levels [59]. The previously reported metabolome data in PRLTS3 patient 58955 where urinary excretion contained excess amounts of fumarate and oxo-glutarate [36] suggest that carbon flux in the TCA cycle occurs at high levels, possibly at the expense of specific amino acids as well as glucose. Abnormal assembly UQCRC2 in mitochondrial complex III could easily explain why its respiratory activity was mildly low in a muscle biopsy of PRLTS3 patient 58955 [36]. High-throughput phenotype screening of the ClpP-null mouse organism previously revealed decreases in circulating insulin level, versus increased circulating cholesterol (https://www.mousephenotype.org/data/genes/MGI:1858213#phenotypesTab) and bilirubin levels. Also studies of the metabolome in ClpP-deficient microorganism *Bacillus subtilis* showed elevated levels for most glycolytic metabolites and TCA intermediates [60]. These subtle and selective effects are compatible with the mild phenotype of ClpP-mutant fibroblasts. Overall, literature and our proteome data suggest that only few specific multimeric complexes are affected (rather than the bulk of monomeric enzymes) in the mitochondrial matrix of ClpP-mutant cells.

### 3.8. Nucleoid misassembly in ClpP-mutant patient fibroblasts

Next, we focused on pathology due to the ClpX interactor excess. Our prior work had documented that deficiency of ClpP in mouse cells leads to mtDNA instability and nucleoid enlargement, but whether these features could be recapitulated in Perrault syndrome patients is unknown [16]. Nucleoid staining in human fibroblasts from control (Red128) and PRLTS3 (CLPP mutant patient 58955) showed mtDNA stress and packaging alterations in PRLTS3 patient (Figure 5A), with significant nucleoid enlargement (Figure 5B). Similarly to ClpP-null MEFs, PRLTS3 patient cells also showed significant increase in mtDNA copy number (Figure 5C) assessed by qPCR with ND1 and DLoop1 mitochondrial DNA primers.
**Figure 5:** Nucleoid misassembly in PRLTS3 fibroblasts. (A) Immunocytochemistry with HSP60 as mitochondrial marker (purple) and DAPI as nuclear marker (blue) showed PRLTS3 fibroblasts with larger TFAM-positive area (red) that contain multiple mitochondrial DNA signals upon deconvolution (green). (B) Quantification of nucleoid size showed significant enlargement. (C) Copy number quantification by qPCR for two sites within mtDNA also revealed significant increase.
4. Discussion

Our study attempted to define mitochondrial ClpP-mediated degradation substrates in mouse and human. This goal was first approached by consistency criteria, comparing proliferating peripheral cells with glycolytic profile from two organisms, versus murine nervous tissue containing postmitotic neurons that have respiratory profile. To distinguish primary events from secondary consequences, high-quality protein interaction data from BioGrid database were used to identify the ClpX protein interactors that accumulate upon ClpP inactivity (Figure 1). In a second approach, the accumulation fold-changes of mitochondrial proteins were correlated to disease severity in two PRLTS3 patients (Figure 4B). Each strategy came to the conclusion that the primary effects of ClpP inactivity involve ClpX interactor proteins at the nucleoid and mitochondrial RNA granule (Figure 6). The fold-changes of accumulation were much stronger for these proteins than what was previously observed for ClpP modulation of mitoribosomal components, and naturally the observed nucleoid / RNA granule pathology might affect mitoribosomal translation as downstream consequence. Numerous previous efforts to define ClpP-mediated degradation substrates had been unable to identify consistent results across species and techniques employed, so we wonder to what degree the interactions between ClpX and its target protein/RNA/DNA complexes may be lost during the different co-immunoprecipitation and extraction procedures used.

![Figure 6](image_url)

**Figure 6:** ClpP inactivating variants act via ClpX accumulation on nucleoid components, triggering excess POLDIP2, LRPPRC, GFM1, GRSF1 and mtDNA abundance. Apparently without ClpX interactions, also multimerizing enzymes in the matrix show increased abundance. In parallel, elevated levels of molecular chaperones suggest mitochondrial unfolded protein response and aggregation tendencies to occur. OAT multimer and nucleoid shapes were adapted from references [61, 62].

As a first key finding, ClpP pathogenic variants trigger the protein accumulation of POLDIP2, LRPPRC and GFM1 with high consistency between mammalian species and cell types. While POLDIP2 functions at the nucleoid and LRPPRC at the mitochondrial RNA granule modulating polyadenylation [40, 41, 63, 64], GFM1 directly acts at mitoribosomes and its excess was shown to impair translation [43, 65, 66]. Mitoribosomal
dysfunction is considered a crucial site of pathology in Perrault syndrome, and these events occur upstream. In addition, the mouse proteome profiles identified the ClpP-dependent accumulation of GRSF1 as prominent (in ClpP-null MEF 4.6-fold and highly significant, in ClpP-null brain pellet 2.1-fold with actual significance, in ClpP-null brain supernatant 1.8-fold with p=0.06, in human fibroblasts it was detected only in 2 among seven controls and was therefore ignored by the filtering algorithm, but imputation revealed a >5-fold highly significant accumulation). GRSF1 acts with RNase P to process mitochondrial polycistronic precursor RNA into tRNAs / mRNAs / rRNAs and lncRNAs [42, 67]. GRSF1 associates with Twinkle in the mitochondrial RNA granule [5], and controls translation of mRNAs with G-repeats in front of the start codon [68, 69]. Thus, GRSF1 connects ClpXP with Twinkle and tRNA maturation in mitochondrial RNA granules. Our crucial novel insight of ClpP-dependent GFM1 and GRSF1 abundance therefore suggests a common pathway for Perrault syndrome pathogenesis, since the genetic causes of autosomal recessive Perrault syndrome include variants in the mitochondrial tRNA amino-acid synthetases HARS2 and LARS2, the mitochondrial tRNA processing enzyme PRORP, the mitochondrial DNA/RNA helicase/primase TWNK, and the peptidase ClpP. It is noteworthy that none of the Perrault syndrome disease proteins was dysregulated, except HSD17B4 that showed a significant upregulation only in patient fibroblasts, so the role of ClpP cannot be explained by abnormal degradation of a Perrault syndrome disease protein.

A second key finding is the relocation of excess amounts of ClpX and its interactors such as GFM1 and GRSF1 outside mitochondria. This might represent an additional mechanism, how retrograde signals about mitochondrial needs and pathology reach the nucleus, in the context of UPRmt but independent from transcriptional regulation, influencing the abundance of nuclear / nucleolar proteins and affecting the whole cell. This ClpX redistribution was observed only in mouse and was not demonstrable in patient fibroblast. As a similar difference between mouse and human, it is interesting to note that the ClpP-null MEF showed a massive induction of the innate immune defence against toxic DNA/RNA, while the patient fibroblasts did not show such immunostimulation. GRSF1 has a physiological presence in the nucleus like other members of the hnRNP F/H family [70], but its function there is not clear. GRSF1 abundance is physiologically controlled by DAZL [71], the master translational regulator of spermatogenesis [72, 73]. It is known that a G4-repeat DNA structure resolvase named RHAU is essential for spermatogonia differentiation via c-Kit [74]. Furthermore, GRSF1 targets the G-repeat containing mRNA of GPx4 [75], a crucial factor for protamine-mediated chromatin condensation [76]. Thus, it is conceivable that dysregulated GRSF1 abundance interferes with germ cell differentiation, meiosis and sperm capacitation in PRLTS3. Primary ovarian insufficiency is also observed upon mutation of the mitochondrial tRNA synthetases HARS2, LARS2 and PRORP, so apparently other mitochondrial tRNA processing alterations may also influence meiotic events in the nucleus.

The weakest effect of ClpP deletion on a ClpX interactor in the above experiments was observed for the PD-associated UPRmt sensor CHCHD2 [24, 44], in agreement with previous observations that ClpP-null mice do not show widespread strong UPRmt [77] or the typical distribution of PD pathology [2, 78].

As third key finding, ClpP-deletion across species and cell types consistently triggers the accumulation of homo/hetero-multimerizing enzymes in the mitochondrial matrix such as OAT, ASS1, ACADVL, STOM, PRDX3, PC, MUT, ALDH2, PMPCB, UQCRC2 and ACADSB. Although the
accumulation of MUT is mild, it correlates best to the metabolome findings of elevated methylmalonyl-CoA and isoleucine levels in ClpP-mutant fibroblasts. MUT acts on methylmalonyl-CoA that is derived from degraded branched chain amino acids such as isoleucine, isomerizing it to succinyl-CoA as substrate for the TCA cycle. Given that MUT has to assemble into homodimers with GTPase-assisted binding to vitamin B12 [79], its optimal activity may not be achieved under mild UPR<sup>mt</sup> stress conditions, leading to accumulations of dysfunctional MUT, its substrate methylmalonyl-CoA and its precursor isoleucine. The reduced levels of methionine as a start codon for protein synthesis might mirror inefficient ribosomal translation. Alternatively, the reduction of methionine together with histidine might point to altered glucogenic metabolism. However, we want to caution against over-interpretation of our metabolomics findings, since 3 alterations with nominal significance among the 54 metabolites investigated might simply be explained away as multiple testing artifact, a false positive result.

As fourth key finding, human cells from ClpP mutant PRLTS3 patients show enlarged nucleoid area and thus confirm the significant role of ClpP in maintenance of mtDNA / protein complex assembly and distribution, which was previously observed in mouse cells with ClpP deficiency. Here it is interesting to note that ClpX was previously reported to modulate the genome distribution in mitochondria, and to enhance the DNA-binding activity of TFAM as requirement for maintaining a normal mitochondrial nucleoid structure [80]. The phenotype observed in PRLTS3 patient cells indicates a potential role for mtDNA stress in the pathogenesis of Perrault syndrome, a scenario that has not been explored before. These findings indicate a conserved role for ClpP in mtDNA homeostasis that might have implications for downstream mitochondrial transcription and translation.

Jointly, the selective accumulation of multimerizing enzymes in the matrix and of mtDNA copies in nucleoids of ClpP mutant cells may suggest that ClpP acts to restrict unwanted further self-assembly, once the appropriate degree of multimerization or the appropriate number of supercoiled DNA rings per nucleoid is reached. According to this notion, ClpP function would limit multimerization and would counteract aggregation and fibril formation in the mitochondrial matrix, rather than having a responsibility for the degradation of bulk proteins like the mitochondrial matrix protease LonP1.

Overall, the present data concur with previous evidence that the PRLTS3 pathology is dominated by improper handling of nucleic acids by proteins, leading to nucleoid pathology in mouse and human as shown here, as well as distorted responses of cytosolic immune sensors to toxic nucleic acids at least in mouse cells as reported before [16, 28]. In comparison, the decrease in metabolites is minor and does not seem to explain the substantial growth deficit of ClpP-deficient organisms.

5. Conclusions

Overall, our analysis of accumulated mitochondrial factors in ClpP-mutants, which are consistent across species and cell types have defined several putative substrates of ClpP-mediated degradation. Among them, POLDIP2, LRPPRC and GFM1 interact with ClpX disaggregate and are therefore particularly credible as primary targets of ClpXP function; their roles for mitochondrial nucleoids and RNA granules explain how nucleoids become misassembled in PRLTS3. The excessive amounts of ClpX and its interactors such as GFM1 and GRSF1 relocalize to the nucleus in ClpP-null
mouse fibroblasts, as evidence of the preferential interaction of ClpX with protein/DNA/RNA complexes. In contrast, the accumulation of multimerizing, often vitamin-associated factors such as OAT, MUT, PMPCB, UQCRC2, PC, ACADVL, PRDX3, ASS1, ALDH2, ACADSB and STOM appears to be independent from ClpX, may occur downstream selectively in glycolytic cell types due to the dysregulation of molecular chaperones under conditions of UPR<sup>mt</sup>, and seems to have minor impact on metabolism.

Supplementary Materials:

The following are available online at www.mdpi.com/xxx/s1
Supplementary Figure S1. Factors with significant (p<0.03) accumulation in the global proteome profile (valid values) of ClpP-null MEFs. The diagram was generated on the STRING web-platform to illustrate their interactions in functional networks. Prominently affected pathways (color code and significance are shown in the upper part of the figure) include the Metabolism of proteins (e.g. mitoribosomal subunits), Chaperones (usually associated with ClpX), Mitochondrion (including also the Iron-sulfur-cluster biogenesis such as LIAS or NFU1, and the Branched-chain amino acid / alpha keto-acid dehydrogenases such as BCKDK, as well as FAD-binding domain proteins such as SDHA, and Pyridoxal phosphate-dependent transferase domain 1 containing factors such as OAT, or several von Willebrand factor A-like domain superfamily members such as mitochondrial VWA8 with its nuclear counterpart VWA5A), and the Cytochrome P450-dependent metabolism of xenobiotics (which depends on mitochondrially synthesized heme).
Supplementary Figure S2. Analyses of protein abundance for two multimerizing proteins in MEF (panel A, n=3) and in human control and patient fibroblast (panel B, n=1). Subcellular fractionation quality and loading were controlled by GAPDH, HSP60, or LAMIN A/C abundance. Panel C: mRNA quantification via RT-qPCR. Expression data were normalized against Tbp mRNA levels. Panel D: Quantification of 53 metabolites in MEF via LC-tandem mass spectrometry revealed
3 dysregulations with nominal significance. Absolute values were normalized against mean WT values. T: 0.05 < p < 0.1, *p < 0.05.

**Supplementary Table S1**: Global proteome data of WT and ClpP-null MEF cells (n=3). The various worksheets contain output data with imputation, and Fisher algorithm statistical output. Factors highlighted with orange background have preferential mitochondrial localization.

**Supplementary Table S2**: Pathway enrichment analyses for non-imputed dysregulations (p<=0.03) global proteome profile of ClpP-null versus WT MEF cells, according to STRING webserver. In 10 different worksheets, the same color code as in Figure S1 was used to emphasize particularly relevant and novel pathways.

**Supplementary Table S3**: Global proteome data of ClpP-null versus WT brain tissue (n= 6 vs. 6), comparing RIPA-soluble supernatant and the resulting pellet dissolved in SDS. Different worksheets provide all raw data, the compiled significant accumulations, and the factors with consistently and significantly elevated abundance in ClpP-null brain and MEF (in order: firstly mitoribosomal components, secondly mitochondrial ClpX interactors and molecular chaperones, third various assembly factors and enzymes in the matrix. Factors with special relevance again are highlighted with bold fonts.

**Supplementary Table S4**: Pathway enrichment analyses in the global proteome profile of ClpP-null versus WT brain tissue, STRING webserver output. Again, color-codes were used in the 11 different worksheets to highlight pathways of particular relevance and novelty, which are discussed in the manuscript.

**Supplementary Table S5**: BioGRID output of protein interactors for human ClpP, ClpX, and ClpB. The different worksheets contain BioGRID original data, protein lists filtered for non-redundant factors, and those interactors that show significant accumulation in ClpP-null proteome profiles. Bold letters again highlight specific factors discussed in the manuscript.

**Supplementary Table S6**: Global proteome profile of primary skin fibroblasts (control n= 7, PRLTS3 n=2 lines in biological triplicates). Mitochondrial proteins are shown in bold letters, the most relevant factors in larger font.

**Supplementary Table S7**: Mitochondrial factors with significant accumulation in ClpP-mutant patient fibroblasts, which was at least 20% stronger in the severe PRLTS3 patient 58955 than in the milder patient 0006.

**Supplementary Table S8**: Metabolome data of ClpP-null versus WT MEF (n=8). Different worksheets contain original values, means, statistical analyses, and normalized data.

**Author Contributions**: Conceptualization: J.K., S.T.-O., S.G., N.C.B., A.P.W., S.A.S., I.W., and G.A.; methodology: J.K., S.T.-O., N.C.B., S.G., G.K, M.R., A.P.W., and I.W.; software: J.K., N.C.B., I.W., and G.A.; validation: M.R., S.G., G.K. and S.T.-O.; formal
analysis: J.K., S.T.-O.; investigation: I.W., A.P.W., W.G.N., and G.A.; resources: S.G., H.P., P.F., W.G.N., S.S. and G.A.; data curation: N.C.B. and I.W.; writing—original draft preparation: J.K. and G.A.; writing—review and editing: J.K., S.T.-O., N.C.B., S.G., A.P.W., H.P., W.G.N., and I.W.; visualization: J.K., N.C.B., S.T.-O., A.P.W. and G.A.; supervision: A.P.W., S.A.S., I.W., and G.A.; project administration: G.A.; funding acquisition: I.W., W.G.N., A.P.W., and G.A.

Funding: This research was mainly supported with internal funds of the Goethe University Frankfurt. I.W. was financed by a grant to the German Network for Mitochondrial Disorders (mitoNET, 01GM1906D). W.G.N. was supported by Action Medical Research GN2494.P.W. and S.T.-O. were supported by the Office of the Assistant Secretary of Defense for Health Affairs, U.S. Department of Defense Awards W81XWH-17-1-0052 and W81XWH-20-1-0150 (to A.P.W.) through the Peer Reviewed Medical Research Programs. Additional support was provided by National Heart, Lung, and Blood Institute, National Institutes of Health (NIH) Grant R01HL148153 (to A.P.W.). Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the NIH or the U.S. Department of Defense.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of Klinikum Goethe Universität Frankfurt/Main (protocol code 117/07, May 24, 2007) and the Wales Research Ethics Committee (protocol code 16/WA/0017 and original approval, February 4, 2016).

Informed Consent Statement: Written informed consent was obtained from all subjects or their guardians involved in the study.

Data Availability Statement: Proteome profiles of MEF and human fibroblasts were deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier: PXD023677 (MEF), PXD029418 (human fibroblasts) (Project Webpage: http://www.ebi.ac.uk/pride/archive/projects/PXD023677).

Acknowledgments: We are grateful for the help received from the staff at the ZFE animal facility of the Medical Faculty of Frankfurt University. Many thanks to Henry Houlden (London, UK) for providing control fibroblast cell lines.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations:

ACADSB    Acyl-CoA Dehydrogenase, Short/ Branched Chain Specific
ACADVL    Acyl-CoA Dehydrogenase, Very-Long Chain
ALDH2     Aldehyde Dehydrogenase, Mitochondrial Isoform
ANOVA     analysis of variance
ASS1      Argininosuccinate synthase 1
BCA       Bicinchorinic acid assay
cGAS      Cyclic GMP-AMP Synthase
CHCHD2    Coiled-Coil-Helix-Coiled-Coil-Helix Domain Containing 2
| Abbreviation | Full Name |
|--------------|-----------|
| c-kit        | tyrosine-protein kinase KIT |
| ClpB         | Caseinolytic Mitochondrial Matrix Peptidase Chaperone Subunit B |
| ClpP         | Caseinolytic Mitochondrial Matrix Peptidase Proteolytic Subunit |
| ClpX         | Caseinolytic Mitochondrial Matrix Peptidase Chaperone Subunit X |
| DAZL         | Deleted In Azoospermia Like |
| DMEM         | Dulbecco’s modified Eagle medium |
| Dnaja3       | DnaJ Heat Shock Protein Family (Hsp40) Member A3 |
| EDTA         | Ethylenediaminetetraacetic acid |
| Eral1        | Era Like 12S Mitochondrial RNA Chaperone 1 |
| ESI          | electrospray ionization |
| FBS          | Fetal bovine serum |
| GAPDH        | Glyceraldehyde-3-Phosphate Dehydrogenase |
| GFM1         | G Elongation Factor Mitochondrial 1 |
| GPx4         | Glutathione Peroxidase 4 |
| GRSF1        | G-Rich RNA Sequence Binding Factor 1 |
| HARS2        | Histidyl-TRNA Synthetase 2, Mitochondrial |
| hnRNP        | Heterogeneous Nuclear Ribonucleoprotein |
| Hsd17b4      | Hydroxysteroid 17-Beta Dehydrogenase 4 |
| HSP60        | Heat Shock Protein Family D (Hsp60) Member 1 |
| LARS2        | Leucyl-TRNA Synthetase 2, Mitochondrial |
| IncRNA       | Long non-coding RNAs |
| LRPPRC       | Leucine Rich Pentatricopeptide Repeat Containing |
| MEF          | mouse embryonic fibroblasts |
| MRM          | multiple reaction mode |
| mRNA         | messenger RNA |
| MRPS22       | Mitochondrial Ribosomal Protein S22 |
| MRPS27       | Mitochondrial Ribosomal Protein S27 |
| MRPS9        | Mitochondrial Ribosomal Protein S9 |
| mtDNA        | mitochondrial DNA |
| MUT          | Methylmalonyl-CoA Mutase |
| OAT          | Ornithine Aminotransferase |
| OXR1         | Oxidation Resistance 1 |
| PC           | Pyruvate Carboxylase |
| PCR          | polymerase chain reaction |
| PD           | Parkinson's disease |
| PMPCA        | Peptidase, Mitochondrial Processing Subunit Alpha |
| PMPCB        | Peptidase, Mitochondrial Processing Subunit Beta |
| POLDIP2      | DNA Polymerase Delta Interacting Protein 2 |
| PRORP        | Protein Only RNase P Catalytic Subunit |
References

1. Newman, W.G., et al., Perrault Syndrome, in GeneReviews(R), M.P. Adam, et al., Editors. 1993: Seattle (WA).
2. Faridi, R., et al., New insights into Perrault syndrome, a clinically and genetically heterogeneous disorder. Hum Genet, 2021.
3. Chatzispyrou, I.A., et al., A homozygous missense mutation in ERAL1, encoding a mitochondrial rRNA chaperone, causes Perrault syndrome. Hum Mol Genet, 2017. 26(13): p. 2541-2550.
4. Hochberg, I., et al., Bi-allelic variants in the mitochondrial RNase P subunit PRORP cause mitochondrial tRNA processing defects and pleiotropic multisystem presentations. Am J Hum Genet, 2021.
5. Hensen, F., et al., Mitochondrial RNA granules are critically dependent on mtDNA replication factors Twinkle and mtSSB. Nucleic Acids Res, 2019. 47(7): p. 3680-3698.
6. Uittenbogaard, M. and A. Chiaramello, Novel subcellular localization of the DNA helicase Twinkle at the kinetochore complex during mitosis in neuronal-like progenitor cells. Histochem Cell Biol, 2016. 145(3): p. 275-86.
7. Haynes, C.M., et al., ClpP mediates activation of a mitochondrial unfolded protein response in C. elegans. Dev Cell, 2007. 13(4): p. 467-80.
8. Zhao, Q., et al., A mitochondrial specific stress response in mammalian cells. EMBO J, 2002. 21(17): p. 4411-9.
9. Wawrzynow, A., et al., The ClpX heat-shock protein of Escherichia coli, the ATP-dependent substrate specificity component of the ClpP-ClpX protease, is a novel molecular chaperone. EMBO J, 1995. 14(9): p. 1867-77.
10. Gersch, M., et al., AAA+ chaperones and acyldepsipeptides activate the ClpP protease via conformational control. Nat Commun, 2015. 6: p. 6320.
11. Hofsetz, E., et al., The Mouse Heart Mitochondria N Terminome Provides Insights into ClpXP-Mediated Proteolysis. Mol Cell Proteomics, 2020. 19(8): p. 1330-1345.
12. Baker, T.A. and R.T. Sauer, ClpXP, an ATP-powered unfolding and protein-degradation machine. Biochim Biophys Acta, 2012. 1823(1): p. 15-28.
13. Lee, S., et al., The ClpB/Hsp104 molecular chaperone-a protein disaggregating machine. J Struct Biol, 2004. 146(1-2): p. 99-105.
14. Gispert, S., et al., Loss of mitochondrial peptidase Clpp leads to infertility, hearing loss plus growth retardation via accumulation of CLPX, mtDNA and inflammatory factors. Hum Mol Genet, 2013. 22(24): p. 4871-87.
15. Szczepanowska, K., et al., CLPP coordinates mitoribosomal assembly through the regulation of ERAL1 levels. EMBO J, 2016. 35(23): p. 2566-2583.
16. Torres-Odio, S., et al., Loss of Mitochondrial Protease CLPP Activates Type I IFN Responses through the Mitochondrial DNA-cGAS-STING Signaling Axis. J Immunol, 2021. 206(8): p. 1890-1900.
17. Key, J., et al., Global Proteome of LonP1(+/−) Mouse Embryonal Fibroblasts Reveals Impact on Respiratory Chain, but No Interdependence between Eral1 and Mitoribosomes. Int J Mol Sci, 2019. 20(18).
18. Becker, C., et al., CLPP deficiency protects against metabolic syndrome but hinders adaptive thermogenesis. EMBO Rep, 2018. 19(5).
19. Bhaskaran, S., et al., Loss of mitochondrial protease ClpP protects mice from diet-induced obesity and insulin resistance. EMBO Rep, 2018. 19(3).
20. Demain, L.A., et al., Expanding the genotypic spectrum of Perrault syndrome. Clin Genet, 2017. 91(2): p. 302-312.
21. Vertika, S., K.K. Singh, and S. Rajender, Mitochondria, spermatogenesis, and male infertility - An update. Mitochondrion, 2020. 54: p. 26-40.
22. Granat, L., R.J. Hunt, and J.M. Bateman, Mitochondrial retrograde signalling in neurological disease. Philos Trans R Soc Lond B Biol Sci, 2020. 375(1801): p. 20190415.
23. Arnould, T., S. Michel, and P. Renard, Mitochondria Retrograde Signaling and the UPR mt: Where Are We in Mammals? Int J Mol Sci, 2015. 16(8): p. 18224-51.
24. Huang, X., et al., CHCHD2 accumulates in distressed mitochondria and facilitates oligomerization of CHCHD10. Hum Mol Genet, 2019. 28(2): p. 349.
25. Zhou, W., et al., PD-linked CHCHD2 mutations impair CHCHD10 and MICOS complex leading to mitochondria dysfunction. Hum Mol Genet, 2019. 28(7): p. 1100-1116.
26. Aras, S., et al., Mitochondrial Nuclear Retrograde Regulator 1 (MNRR1) rescues the cellular phenotype of MELAS by inducing homeostatic mechanisms. Proc Natl Acad Sci U S A, 2020. 117(50): p. 32056-32065.
27. Key, J., et al., Loss of mitochondrial ClpP, Lonp1, and Tfam triggers transcriptional induction of Rnf213, a susceptibility factor for moyamoya disease. Neurogenetics, 2020. 21(3): p. 187-203.
28. Maletzko, A., et al., Increased presence of nuclear DNAJA3 and upregulation of cytosolic STAT1 and of nucleic acid sensors trigger innate immunity in the ClpP-null mouse. Neurogenetics, 2021. 22(4): p. 297-312.
29. Wan, L., et al., Translation stress and collided ribosomes are co-activators of cGAS. Mol Cell, 2021. 81(13): p. 2808-2822 e10.
30. Perez-Riverol, Y., et al., The PRIDE database and related tools and resources in 2019: improving support for quantitation data. Nucleic Acids Res, 2019. 47(D1): p. D442-D450.
31. Tyanova, S. and J. Cox, Perseus: A Bioinformatics Platform for Integrative Analysis of Proteomics Data in Cancer Research. Methods Mol Biol, 2018. 1711: p. 133-148.
32. Wisniewski, J.R., et al., Universal sample preparation method for proteome analysis. Nat Methods, 2009. 6(5): p. 359-62.
33. Kulak, N.A., et al., Minimal, encapsulated proteomic-sample processing applied to copy-number estimation in eukaryotic cells. Nat Methods, 2014. 11(3): p. 319-24.
34. Cox, J. and M. Mann, MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol, 2008. 26(12): p. 1367-72.
35. Eden, E., et al., GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics, 2009. 10: p. 48.
36. Kremer, L.S., et al., Genetic diagnosis of Mendelian disorders via RNA sequencing. Nat Commun, 2017. 8: p. 15824.
37. Wessel, D. and U.I. Flugge, A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem, 1984. 138(1): p. 141-3.
38. Schmittgen, T.D. and K.J. Livak, Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc, 2008. 3(6): p. 1101-8.
39. Luo, M., et al., Von Willebrand factor A domain-containing protein 8 (VWA8) localizes to the matrix side of the inner mitochondrial membrane. Biochem Biophys Res Commun, 2020. 521(1): p. 158-163.
40. Cheng, X., et al., PDP38 associates with proteins constituting the mitochondrial DNA nucleoid. J Biol Chem, 2005. 138(6): p. 673-8.
41. Bruni, F., et al., Messenger RNA delivery to mitoribosomes - hints from a bacterial toxin. FEBS J, 2021. 288(2): p. 437-451.
42. Jourdain, A.A., et al., GRSF1 regulates RNA processing in mitochondrial RNA granules. Cell Metab, 2013. 17(3): p. 399-410.
43. Koripella, R.K., et al., Structures of the human mitochondrial ribosome bound to EF-G1 reveal distinct features of mitochondrial translation elongation. Nat Commun, 2020. 11(1): p. 3830.
44. Meng, H., et al., Loss of Parkinson’s disease-associated protein CHCHD2 affects mitochondrial crist structure and destabilizes cytochrome c. Nat Commun, 2017. 8: p. 15500.
45. Wilson, W.C., et al., A human mitochondrial poly(A) polymerase mutation reveals the complexities of post-transcriptional mitochondrial gene expression. Hum Mol Genet, 2014. 23(23): p. 6345-55.
46. Antonicka, H. and E.A. Shoubridge, Mitochondrial RNA Granules Are Centers for Posttranscriptional RNA Processing and Ribosome Biogenesis. Cell Rep, 2015. 10(6): p. 920-932.
47. Shevell, M.L., et al., Varying neurological phenotypes among muto and mut- patients with methylmalonyl-CoA mutase deficiency. Am J Med Genet, 1993. 45(5): p. 619-24.
48. Taoka, S., et al., Inhibition of the human methylmalonyl-CoA mutase by various CoA-esters. J Biol Chem, 1994. 269(50): p. 31630-4.
49. Lunsdorf, H., H.J. Hecht, and H. Tsai, High-resolution electron microscopic studies on the quaternary structure of ornithine aminotransferase from pig kidney. Eur J Biochem, 1994. 225(1): p. 205-11.
50. Taylor, A.B., et al., Crystal structures of mitochondrial processing peptidase reveal the mode for specific cleavage of import signal sequences. Structure, 2001. 9(7): p. 615-25.
51. Fernandez-Vizarra, E. and M. Zeviani, Mitochondrial complex III Rieske Fe-S protein processing and assembly. Cell Cycle, 2018. 17(6): p. 681-687.
52. Choi, P.H., et al., A distinct holoenzyme organization for two-subunit pyruvate carboxylase. Nat Commun, 2016. 7: p. 12713.
53. McAndrew, R.P., et al., Structural basis for substrate fatty acyl chain specificity: crystal structure of human very-long-chain acyl-CoA dehydrogenase. J Biol Chem, 2008. 283(14): p. 9435-43.
54. Yewdall, N.A., et al., Structures of Human Peroxiredoxin 3 Suggest Self-Chaperoning Assembly that Maintains Catalytic State. Structure, 2016. 24(7): p. 1120-9.
55. Karlberg, T., et al., Structure of human argininosuccinate synthetase. Acta Crystallogr D Biol Crystallogr, 2008. 64(Pt 3): p. 279-86.
56. Matsumoto, S., et al., E487K-Induced Disorder in Functionally Relevant Dynamics of Mitochondrial Aldehyde Dehydrogenase 2. Biophys J, 2020. 119(3): p. 628-637.
57. Battaile, K.P., et al., Crystal structure of rat short chain acyl-CoA dehydrogenase complexed with acetoacetyl-CoA: comparison with other acyl-CoA dehydrogenases. J Biol Chem, 2002. 277(14): p. 12200-7.
58. Snyers, L., E. Umlauf, and R. Prohaska, Oligomeric nature of the integral membrane protein stomatin. J Biol Chem, 1998. 273(27): p. 17221-6.
59. Heinz, D., et al., Simultaneous Ablation of the Catalytic AMPK alpha-Subunit SNF1 and Mitochondrial Matrix Protease CLPP Results in Pronounced Lifespan Extension. Front Cell Dev Biol, 2021. 9: p. 616520.
60. Schultz, D., et al., Metabolic Perturbations in a Bacillus subtilis clpP Mutant during Glucose Starvation. Metabolites, 2017. 7(4).
61. Shen, B.W., et al., Crystal structure of human recombinant ornithine aminotransferase. J Mol Biol, 1998. 277(1): p. 81-102.
62. Bonekamp, N.A. and N.G. Larsson, *SnapShot: Mitochondrial Nucleoid*. Cell, 2018. **172**(1-2): p. 388-388 e1.

63. Uchiumi, T. and D. Kang, *Mitochondrial nucleic acid binding proteins associated with diseases*. Front Biosci (Landmark Ed), 2017. **22**: p. 168-179.

64. Sasarman, F., et al., *LRPPRC and SLIRP interact in a ribonucleoprotein complex that regulates posttranscriptional gene expression in mitochondria*. Mol Biol Cell, 2010. **21**(8): p. 1315-23.

65. Kummer, E. and N. Ban, *Structural insights into mammalian mitochondrial translation elongation catalyzed by mtEFG1*. EMBO J, 2020. **39**(15): p. e104820.

66. Antonicka, H., et al., *The molecular basis for tissue specificity of the oxidative phosphorylation deficiencies in patients with mutations in the mitochondrial translation factor EFG1*. Hum Mol Genet, 2006. **15**(11): p. 1835-46.

67. Antonicka, H., et al., *The mitochondrial RNA-binding protein GRSF1 localizes to RNA granules and is required for posttranscriptional mitochondrial gene expression*. Cell Metab, 2013. **17**(3): p. 386-98.

68. Nieradka, A., et al., *Grsf1-induced translation of the SNARE protein Use1 is required for expansion of the erythroid compartment*. PLoS One, 2014. **9**(9): p. e104631.

69. Pietras, Z., et al., *Dedicated surveillance mechanism controls G-quadruplex forming non-coding RNAs in human mitochondria*. Nat Commun, 2018. **9**(1): p. 2558.

70. Dumoulin, B., et al., *Expression Regulation, Protein Chemistry and Functional Biology of the Guanine-Rich Sequence Binding Factor 1 (GRSF1)*. J Mol Biol, 2021. **433**(13): p. 166922.

71. Jiao, X., P. Trifillis, and M. Kiledjian, *Identification of target messenger RNA substrates for the murine deleted in azoospermia-like RNA-binding protein*. Biol Reprod, 2002. **66**(2): p. 475-85.

72. Fu, X.F., et al., *DAZ Family Proteins, Key Players for Germ Cell Development*. Int J Biol Sci, 2015. **11**(10): p. 1226-35.

73. Li, H., et al., *DAZL is a master translational regulator of murine spermatogenesis*. Natl Sci Rev, 2019. **6**(3): p. 455-468.

74. Gao, X., et al., *A G-quadruplex DNA structure resolvase, RHAU, is essential for spermatogonia differentiation*. Cell Death Dis, 2015. **6**: p. e1610.

75. Ufer, C., et al., *Translational regulation of glutathione peroxidase 4 expression through guanine-rich sequence-binding factor 1 is essential for embryonic brain development*. Genes Dev, 2008. **22**(13): p. 1838-50.

76. Puglisi, R., et al., *The nuclear form of glutathione peroxidase 4 colocalizes and directly interacts with protamines in the nuclear matrix during mouse sperm chromatin assembly*. Spermatogenesis, 2014. **4**: p. e28460.

77. Seiferling, D., et al., *Loss of CLPP alleviates mitochondrial cardiomyopathy without affecting the mammalian UPRmt*. EMBO Rep, 2016. **17**(7): p. 953-64.

78. Gottschalk, M.E., S.B. Coker, and L.A. Fox, *Neurologic anomalies of Perrault syndrome*. Am J Med Genet, 1996. **65**(4): p. 274-6.

79. Froese, D.S., et al., *Structures of the human GTPase MMAA and vitamin B12-dependent methylmalonyl-CoA mutase and insight into their complex formation*. J Biol Chem, 2010. **285**(49): p. 38204-13.

80. Kasashima, K., M. Sumitani, and H. Endo, *Maintenance of mitochondrial genome distribution by mitochondrial AAA+ protein ClpX*. Exp Cell Res, 2012. **318**(18): p. 2335-43.